Contents

Current Drug Targets - CNS & Neurological Disorders, Volume 3 - Number 3

Small Conductance Ca2+-Activated K+ Channels as Targets of CNS Drug Development

, 3(3): 161 - 167

Thomas Blank, Ingrid Nijholt, Min-Jeong Kye and Joachim Spiess


DOI: 10.2174/1568007043337472




The NR2B Subtype of NMDA Receptor: A Potential Target for the Treatment of Alcohol Dependence

, 3(3): 169 - 179

Jozsef Nagy


DOI: 10.2174/1568007043337409




AMPA Receptor Potentiators for the Treatment of CNS Disorders

, 3(3): 181 - 194

Michael J. O'Neill, David Bleakman, Dennis M. Zimmerman and Eric S. Nisenbaum


DOI: 10.2174/1568007043337508




Methods for Providing Therapeutic Agents to Treat Damaged Spiral Ganglion Neurons

, 3(3): 195 - 199

L. M. Bianchi and Y. Raz


DOI: 10.2174/1568007043337454




The Mechanism of Action of Antidepressants: A Unitary Hypothesis Based on Transport-P

, 3(3): 201 - 216

Saad Al-Damluji


DOI: 10.2174/1568007043337562




Antipsychotic Drugs: Evolving Mechanisms of Action with Improved Therapeutic Benefits

, 3(3): 217 - 226

B. Dean and E. Scarr


DOI: 10.2174/1568007043337373




Programmed Axon Death, Synaptic Dysfunction and the Ubiquitin Proteasome System

, 3(3): 227 - 238

M. P. Coleman and R. R. Ribchester


DOI: 10.2174/1568007043337436




Astrocytic Adrenoceptors: A Major Drug Target in Neurological and Psychiatric Disorders?

, 3(3): 239 - 268

L. Hertz, Y. Chen, M. E. Gibbs, P. Zang and L. Peng


DOI: 10.2174/1568007043337535




Webmaster Contact: info@benthamscience.org
Copyright © 2018 Bentham Science